Women’s heart attack diagnosis is entering a more precise era

Women’s heart attack diagnosis is being redesigned around a basic clinical reality: the same disease does not always produce the same test pattern in women and men. Newly agreed international guidance introduces sex-specific diagnostic thresholds and more clearly recognises causes of heart injury that conventional pathways have often missed.

This is an important form of health innovation. Progress does not always arrive as a wearable, implant or artificial intelligence model. Sometimes it comes from changing the rules used to interpret biomarkers, symptoms and imaging. In cardiovascular care, where women have historically been diagnosed later and treated less aggressively, that change could alter who receives urgent care and how quickly.

The wider lesson for FemTech is equally relevant. A measurement only becomes useful when it is interpreted against the right reference range, biological context and population. Collecting more data is not enough if the system applying meaning to it was built around an incomplete picture of women’s physiology.

Why women’s heart attack diagnosis needed an update

A heart attack occurs when blood flow to heart muscle is reduced or interrupted, causing injury. Clinicians usually combine symptoms, an electrocardiogram, imaging and changes in cardiac troponin, a protein released into the blood when heart muscle is damaged.

Historically, many diagnostic systems have relied on a single troponin threshold for everyone. Women tend to have lower baseline and peak troponin concentrations than men, partly reflecting average differences in heart size and muscle mass. A universal cut-off can therefore classify a clinically meaningful rise in a woman as normal, delaying further investigation or treatment.

Sex-specific thresholds are intended to reduce that blind spot. They do not mean that every elevated result confirms a heart attack. Troponin can rise with myocarditis, severe infection, pulmonary embolism, kidney disease and other forms of cardiac strain. Its value comes from interpreting the concentration and its change over time alongside symptoms, examination findings, ECG results and imaging.

This distinction matters because precision medicine is not simply about lowering a number for women. It is about using evidence-based thresholds that improve sensitivity without creating unnecessary diagnoses. The effect of the new definition will need to be evaluated in routine care, including whether it changes treatment, outcomes and false-positive rates across different ages and ethnic groups.

A broader definition may reveal overlooked mechanisms

The classic model of a heart attack is a major coronary artery blocked by a ruptured cholesterol plaque and blood clot. That remains common, but it does not account for every event. Women are more likely than men to experience several less familiar mechanisms, including spontaneous coronary artery dissection, coronary artery spasm and dysfunction in the heart’s smallest blood vessels.

Some people also have myocardial infarction with non-obstructive coronary arteries, often abbreviated as MINOCA. This is not one diagnosis but a working category that can include several underlying causes. A standard angiogram may show no major blockage, yet the heart muscle has still been injured. More detailed imaging or functional testing may be required to identify what happened.

By formally recognising a wider range of mechanisms, the updated framework may reduce the tendency to treat a clear angiogram as proof that nothing serious occurred. This is particularly relevant to women whose symptoms, biomarker pattern or artery structure does not fit the traditional template.

Technology can support this shift through high-sensitivity troponin tests, advanced cardiac imaging and decision-support tools. However, each system needs validation in women. An algorithm trained on historical records can reproduce old diagnostic gaps if those records contain fewer confirmed cases in women or reflect years of under-recognition.

Symptoms still require context, not stereotypes

Chest pressure, tightness or discomfort remains a common heart attack symptom in women. Breathlessness, nausea, sweating, unusual fatigue, upper-back or jaw discomfort, dizziness and indigestion-like sensations may also occur. These are sometimes described as “atypical,” but that label can be misleading when the experiences are common in a substantial part of the population.

No symptom list can reliably diagnose or exclude a heart attack. Many of these sensations also occur with reflux, anxiety, viral illness, musculoskeletal pain and hormonal changes. The aim of sex-aware medicine is not to make every episode alarming. It is to prevent assumptions about age, sex or symptom style from overriding objective assessment when acute cardiac injury is possible.

Menopause adds another layer of context. Cardiovascular risk rises with age, and the menopausal transition is associated with changes in lipids, blood pressure, body composition, insulin sensitivity and vascular function. Hormonal symptoms such as palpitations, sleep disruption and heat episodes can overlap with cardiovascular complaints, but new, severe or exertional symptoms should not automatically be attributed to menopause.

The new standards concern clinical diagnosis rather than home screening. Consumer wearables may identify heart rate changes or certain rhythm irregularities, but they cannot measure cardiac troponin or rule out a heart attack. A normal wearable reading should not be treated as reassurance during persistent chest discomfort, breathlessness, faintness or other acute symptoms.

Better thresholds are only part of the innovation

Diagnostic reform succeeds only if it changes practice. Laboratories need to report appropriate reference limits, electronic systems need to apply them correctly, and clinicians need pathways for investigating heart injury without a large obstructive clot. Emergency access and follow-up also matter. Policy research indicating that women may be disproportionately exposed to disruptions in health coverage shows how easily a technical advance can be weakened by barriers to care.

There is also a prevention opportunity. Blood pressure, cholesterol, glucose regulation, smoking or vaping exposure, sleep and activity all influence cardiovascular risk. Digital tools may help reveal trends, but they should complement validated measurements and clinical assessment rather than claim to predict an acute event from general wellness signals.

For women, the most promising direction is not a single new gadget. It is an integrated system in which biomarkers use sex-appropriate ranges, imaging searches for female-relevant mechanisms, algorithms are audited for bias, and symptoms are interpreted without outdated assumptions. That is a more rigorous model of personalised medicine.

Everyday signals such as sleep quality, energy, palpitations and training recovery only become readable as personal patterns when logged consistently over weeks. This is the kind of pattern Tulsy is built to surface, while acute or severe symptoms still require timely medical assessment.

Sources: The Guardian, Medical Xpress.

This content is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, and should not replace advice from a qualified healthcare professional.